The CA IX inhibitor, Indisulam, is currently being evaluated in clinical trials for the treatment of a range of cancers, including metastatic melanoma, lung, acute myeloid leukemia (AML) and metastatic breast cancer where brain metastasis is commonly observed [5]. The gene discussed is CA9; the disease is cancer.